Regulation of spinal dynorphin 1-17 release by endogenous pituitary adenylyl cyclase-activating polypeptide in the male rat: Relevance of excitation via disinhibition

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 328-335

  Liu, Nai Jiang ^a   Schnell, Stephen A ^b   Schulz, Stefan ^c   Wessendorf, Martin W ^b   Gintzler, Alan R ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN A; KAPPA OPIATE RECEPTOR; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; PITUITARY ADENYLYL CYCLASE ACTIVATING POLYPEPTIDE; PITUITARY ADENYLYL CYCLASE ACTIVATING POLYPEPTIDE1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; FUNCTIONAL ANATOMY; IMMUNOREACTIVITY; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SENSORY NERVE CONDUCTION; SPINAL CORD;

ANALGESICS; ANIMALS; DYNORPHINS; MALE; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SPINAL CORD;

EID: 78751470523     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173039     Document Type: Article

References (42)

1. Arvidsson U, Riedl M, Chakrabarti S, Vulchanova L, Lee JH, Nakano AH, Lin X, Loh HH, Law PY, and Wessendorf MW (1995) The κ-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc Natl Acad Sci USA 92:5062-5066.
2. Chery-Croze S, Bosshard A, and Chayvialle JA (1986) Pregnancy-induced increase of spinal cord peptide concentrations in rats. Peptides 7(Suppl 1):197-200.
3. Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, Scott VE, and Honore P (2008) Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J Pain 9:449-456.
4. Dawson-Basoa ME and Gintzler AR (1996) Estrogen and progesterone activate spinal κ-opiate receptor analgesic mechanisms. Pain 64:608-615.
5. Dawson-Basoa M and Gintzler AR (1998) Gestational and ovarian sex steroid antinociception: synergy between spinal κ and δ opioid systems. Brain Research 794:61-67. (Pubitemid 28298865)
6. Dickinson T and Fleetwood-Walker SM (1999) VIP and PACAP: very important in pain? Trends Pharmacol Sci 20:324-329.
7. Dickinson T, Fleetwood-Walker SM, Mitchell R, and Lutz EM (1997) Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31:175-185.
8. Edelbauer H, Lechner SG, Mayer M, Scholze T, and Boehm S (2005) Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin. J Neurochem 93:1110-1121.
9. El-Sobky A, Dostrovsky JO, and Wall PD (1976) Lack of effect of naloxone on pain perception in humans. Nature 263:783-784.
10. Gintzler AR (1980) Endorphin-mediated increases in pain threshold during pregnancy. Science 210:193-195.
11. Gintzler AR, Schnell SA, Gupta DS, Liu NJ, and Wessendorf MW (2008) Relationship of spinal dynorphin neurons to δ-opioid receptors and estrogen receptor α: anatomical basis for ovarian sex steroid opioid antinociception. J Pharmacol Exp Ther 326:725-731.
12. Grevert P and Goldstein A (1978) Endorphins: naloxone fails to alter experimental pain or mood in humans. Science 199:1093-1095.
13. Guirimand F, Strimbu-Gozariu M, Willer JC, and Le Bars D (1994) Effects of μ, δ, and κ opioid antagonists on the depression of a C-fiber reflex by intrathecal morphine and DAGO in the rat. J Pharmacol Exp Ther 269:1007-1020.
14. Gupta DS, Kelson AB, Polgar WE, Toll L, Szücs M, and Gintzler AR (2001) Ovarian sex steroid-dependent plasticity of nociceptin/orphanin FQ and opioid modulation of spinal dynorphin release. J Pharmacol Exp Ther 298:1213-1220.
15. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
16. Jessell TM and Iversen LL (1977) Opiate analgesics inhibit substance P release from rat trigeminal nucleus. Nature 268:549-551.
17. Kamaishi H, Endoh T, and Suzuki T (2004) Multiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons. Auton Neurosci 111:15-26. (Pubitemid 38510611)
18. Kream RM, Kato T, Shimonaka H, Marchand JE, and Wurm WH (1993) Substance P markedly potentiates the antinociceptive effects of morphine sulfate administered at the spinal level. Proc Natl Acad Sci USA 90:3564-3568.
19. Lai J, Ossipov MH, Vanderah TW, Malan TP Jr, and Porreca F (2001) Neuropathic pain: the paradox of dynorphin. Mol Interv 1:160-167.
20. Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, and Wilcox GL (1997) Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 72:253-260.
21. Long JB, Petras JM, Mobley WC, and Holaday JW (1988) Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory, and autonomic function. J Pharmacol Exp Ther 246:1167-1174.
22. Medina VM, Dawson-Basoa ME, and Gintzler AR (1993a) 17-β-Estradiol and progesterone positively modulate spinal cord dynorphin: relevance to the analgesia of pregnancy. Neuroendocrinology 58:310-315.
23. Medina VM, Gupta D, and Gintzler AR (1995) Spinal cord dynorphin precursor intermediates decline during late gestation. J Neurochem 65:1374-1380.
24. Medina VM, Wang L, and Gintzler AR (1993b) Spinal cord dynorphin: positive region-specific modulation during pregnancy and parturition. Brain Res 623:41-46.
25. Moller K, Zhang YZ, Håkanson R, Luts A, Sjölund B, Uddman R, and Sundler F (1993) Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57:725-732.
26. Murakami Y, Koshimura K, Yamauchi K, Nishiki M, Tanaka J, Furuya H, Miyake T, and Kato Y (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates growth hormone release from GH3 cells through type II PACAP receptor. Regul Pept 56:35-40.
27. Ohsawa M, Brailoiu GC, Shiraki M, Dun NJ, Paul K, and Tseng LF (2002) Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain 100:27-34.
28. Ohtaki T, Ogi K, Masuda Y, Mitsuoka K, Fujiyoshi Y, Kitada C, Sawada H, Onda H, and Fujino M (1998) Expression, purification, and reconstitution of receptor for pituitary adenylate cyclase-activating polypeptide. large-scale purification of a functionally active G protein-coupled receptor produced in Sf9 insect cells. J Biol Chem 273:15464-15473. (Pubitemid 28298154)
29. Ossipov MH, Kovelowski CJ, Wheeler-Aceto H, Cowan A, Hunter JC, Lai J, Malan TP Jr, and Porreca F (1996) Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid κ and δ inhibitory tone. J Pharmacol Exp Ther 277:784-788.
30. Papka RE, Workley M, Usip S, Mowa CN, and Fahrenkrug J (2006) Expression of pituitary adenylate cyclase activating peptide in the uterine cervix, lumbosacral dorsal root ganglia and spinal cord of rats during pregnancy. Peptides 27:743-752.
31. Peterson GL and Hokin LE (1981) Molecular weight and stoichiometry of the sodiumand potassium-activated adenosine triphosphatase subunits. J Biol Chem256:3751-3761.
32. Rawlings SR, Demaurex N, and Schlegel W (1994) Pituitary adenylate cyclase-activating polypeptide increases [Ca2]i in rat gonadotrophs through an inositol trisphosphate-dependent mechanism. J Biol Chem 269:5680-5686.
33. Robertson LJ, Hammond GR, and Drummond PD (2008) The effect of subcutaneous naloxone on experimentally induced pain. J Pain 9:79-87.
34. Schulz S, Rocken C, Mawrin C, Weise W, and Hollt V (2004) Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res 10:8235-8242.
35. Shimizu T, Katahira M, Sugawara H, Inoue K, and Miyata A (2004) Diverse effects of intrathecal pituitary adenylate cyclase-activating polypeptide on nociceptive transmission in mice spinal cord. Regul Pept 123:117-122.
36. Shivers BD, Görcs TJ, Gottschall PE, and Arimura A (1991) Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 128:3055-3065.
37. Vanderah TW, Laughlin T, Lashbrook JM, Nichols ML, Wilcox GL, Ossipov MH, Malan TP Jr, and Porreca F (1996) Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 68:275-281.
38. Van Rampelbergh J, Poloczek P, Françoys I, Delporte C, Winand J, Robberecht P, and Waelbroeck M (1997) The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim Biophys Acta 1357:249-255.
39. Xu M, Petraschka M, McLaughlin JP, Westenbroek RE, Caron MG, Lefkowitz RJ, Czyzyk TA, Pintar JE, Terman GW, and Chavkin C (2004) Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci 24:4576-4584.
40. Xu XJ and Wiesenfeld-Hallin Z (1996) Intrathecal pituitary adenylate cyclase activating polypeptide facilitates the spinal nociceptive flexor reflex in the rat. Neuroscience 72:801-804.
41. Yaksh TL, Jessell TM, Gamse R, Mudge AW, and Leeman SE (1980) Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature 286:155-157. (Pubitemid 10013859)
42. Younger JW, Zautra AJ, and Cummins ET (2009) Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology. PLoS One 4:e5180.